RS62412B1 - Jedinjenja platine funkcionalizovana sa monomaleimidom za terapiju raka - Google Patents

Jedinjenja platine funkcionalizovana sa monomaleimidom za terapiju raka

Info

Publication number
RS62412B1
RS62412B1 RS20211187A RSP20211187A RS62412B1 RS 62412 B1 RS62412 B1 RS 62412B1 RS 20211187 A RS20211187 A RS 20211187A RS P20211187 A RSP20211187 A RS P20211187A RS 62412 B1 RS62412 B1 RS 62412B1
Authority
RS
Serbia
Prior art keywords
8alkyl
3alkylene
cancer
compound
solvate
Prior art date
Application number
RS20211187A
Other languages
English (en)
Serbian (sr)
Inventor
Christian Kowol
Petra Heffeter
Walter Berger
Bernhard K Keppler
Josef Mayr
Verena Pichler
Original Assignee
Univ Wien Med
Univ Wien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wien Med, Univ Wien filed Critical Univ Wien Med
Publication of RS62412B1 publication Critical patent/RS62412B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086Platinum compounds
    • C07F15/0093Platinum compounds without a metal-carbon linkage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20211187A 2015-12-09 2016-12-09 Jedinjenja platine funkcionalizovana sa monomaleimidom za terapiju raka RS62412B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15198739 2015-12-09
PCT/EP2016/080453 WO2017097986A1 (en) 2015-12-09 2016-12-09 Monomaleimide-functionalized platinum compounds for cancer therapy
EP16822917.7A EP3386997B1 (en) 2015-12-09 2016-12-09 Monomaleimide-functionalized platinum compounds for cancer therapy

Publications (1)

Publication Number Publication Date
RS62412B1 true RS62412B1 (sr) 2021-10-29

Family

ID=54849106

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20211187A RS62412B1 (sr) 2015-12-09 2016-12-09 Jedinjenja platine funkcionalizovana sa monomaleimidom za terapiju raka

Country Status (21)

Country Link
US (2) US10723748B2 (OSRAM)
EP (1) EP3386997B1 (OSRAM)
JP (1) JP6867652B2 (OSRAM)
CN (1) CN108368143B (OSRAM)
AU (1) AU2016367306B2 (OSRAM)
CA (1) CA3004630A1 (OSRAM)
CY (1) CY1124529T1 (OSRAM)
DK (1) DK3386997T3 (OSRAM)
ES (1) ES2898704T3 (OSRAM)
HR (1) HRP20211466T1 (OSRAM)
HU (1) HUE056897T2 (OSRAM)
IL (1) IL259864B (OSRAM)
LT (1) LT3386997T (OSRAM)
MX (1) MX377528B (OSRAM)
PL (1) PL3386997T3 (OSRAM)
PT (1) PT3386997T (OSRAM)
RS (1) RS62412B1 (OSRAM)
SG (1) SG11201804885TA (OSRAM)
SI (1) SI3386997T1 (OSRAM)
SM (1) SMT202100709T1 (OSRAM)
WO (1) WO2017097986A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200250A1 (en) * 2014-06-23 2015-12-30 Blend Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
CN109171001A (zh) * 2018-09-14 2019-01-11 上海烟草集团有限责任公司 草酸钠在降低卷烟烟气中TSNAs释放量中的应用
EP4085053A4 (en) * 2019-12-31 2023-12-27 Kinnate Biopharma Inc. TREATING CANCER WITH CDK12/13 INHIBITORS
CN114163479B (zh) * 2020-09-11 2025-05-16 上海海聚生物科技有限公司 一类治疗癌症用的铂类化合物及其制备方法
US20230339997A1 (en) * 2020-09-11 2023-10-26 Shanghai Haiju Biological Technology Co., Ltd. Class of platinum compounds for treating cancer, and method for preparation thereof
CN114539320A (zh) * 2020-11-25 2022-05-27 北京大学 辐射激活的四价铂配合物及其用途

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH605550A5 (OSRAM) 1972-06-08 1978-09-29 Research Corp
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS607934A (ja) 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソ−ムの製造方法
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
CS269719B1 (en) 1986-12-29 1990-05-14 Kiss Frantisek Platinum cytostatic
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
KR100575070B1 (ko) 1997-09-29 2006-05-03 넥타르 테라퓨틱스 안정화된 생활성 제제 및 이의 사용 방법
JP4169478B2 (ja) 1998-04-21 2008-10-22 マイクロメット アーゲー Cd19×cd3特異的ポリペプチドおよびその使用
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
AUPQ641100A0 (en) 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
DE10314780A1 (de) 2003-03-19 2004-09-30 Ktb Tumorforschungsgesellschaft Mbh Proteinbindende Derivate von Platinkomplexen mit Cyclobutan-1,1-dicarboxylatliganden
EP1608358A1 (en) 2003-03-31 2005-12-28 Pliva-Lachema A.S. Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof
CZ296169B6 (cs) 2004-09-08 2006-01-11 Pliva - Lachema A. S. Farmaceutická kompozice pro rektální nebo vaginální podání, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
CZ296459B6 (cs) 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
US20060205810A1 (en) 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
CZ300590B6 (cs) 2006-06-20 2009-06-24 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
CZ300424B6 (cs) 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání
CZ300120B6 (cs) 2006-06-20 2009-02-11 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
WO2013085925A1 (en) 2011-12-05 2013-06-13 Igenica, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
MX366864B (es) * 2012-02-27 2019-07-26 Amunix Operating Inc Composiciones de conjugados de xten y métodos para realizarlas.
WO2015052516A1 (en) * 2013-10-08 2015-04-16 Atlas Genetics Limited Labelling compounds and their use in assays
WO2015102922A1 (en) * 2013-12-31 2015-07-09 Blend Therapeutics, Inc. Compounds, compositions, and methods for the treatment of cancers
WO2015200250A1 (en) * 2014-06-23 2015-12-30 Blend Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
EP3313393A4 (en) 2015-06-23 2019-01-09 Placon Therapeutics, Inc. PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF
WO2016209918A1 (en) 2015-06-23 2016-12-29 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
EP3313527B1 (en) 2015-06-29 2021-02-24 Case Western Reserve University Anticancer drug-containing plant virus particles
CN108449940B (zh) 2015-07-12 2021-06-08 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
EP3482205A1 (en) 2016-07-08 2019-05-15 H. Hoffnabb-La Roche Ag Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
WO2018026742A1 (en) 2016-08-01 2018-02-08 Askgene Pharma Inc. Novel antibody-albumin-drug conjugates (aadc) and methods for using them
CN108164512B (zh) 2017-12-27 2021-05-25 沈阳药科大学 一类具有生物粘附作用的马来酰亚胺型前药及其在口服药物传递中的应用
CN108187063B (zh) 2018-01-09 2020-09-08 沈阳药科大学 白蛋白结合型抗肿瘤药-马来酰亚胺分子前药

Also Published As

Publication number Publication date
IL259864A (en) 2018-07-31
LT3386997T (lt) 2021-12-10
CN108368143A (zh) 2018-08-03
DK3386997T3 (da) 2021-09-20
SI3386997T1 (sl) 2021-11-30
SMT202100709T1 (it) 2022-01-10
AU2016367306A1 (en) 2018-06-14
HUE056897T2 (hu) 2022-03-28
JP6867652B2 (ja) 2021-05-12
CN108368143B (zh) 2022-02-01
MX377528B (es) 2025-03-10
MX2018006953A (es) 2019-05-16
EP3386997A1 (en) 2018-10-17
PL3386997T3 (pl) 2021-12-13
US20210002313A1 (en) 2021-01-07
US11572379B2 (en) 2023-02-07
EP3386997B1 (en) 2021-06-30
ES2898704T3 (es) 2022-03-08
PT3386997T (pt) 2021-11-04
US20180354979A1 (en) 2018-12-13
CY1124529T1 (el) 2022-07-22
WO2017097986A1 (en) 2017-06-15
CA3004630A1 (en) 2017-06-15
AU2016367306B2 (en) 2021-04-22
US10723748B2 (en) 2020-07-28
SG11201804885TA (en) 2018-07-30
JP2018538292A (ja) 2018-12-27
IL259864B (en) 2022-07-01
HRP20211466T1 (hr) 2021-12-24

Similar Documents

Publication Publication Date Title
US11572379B2 (en) Monomaleimide-functionalized platinum compounds for cancer therapy
KR101915452B1 (ko) 백금 화합물, 조성물 및 이의 용도
CN110177581B (zh) 髓过氧化物酶显像剂
US10189797B2 (en) Chemical modulators of immune checkpoints and therapeutic use
TR201807023T4 (tr) Abl1, abl2 ve bcr- abl1 aktivitesinin inhibe edilmesi için benzamid türevleri.
AU2014239254B2 (en) Crystalline forms of tyrosine kinase inhibitors and their salts
CN114585625A (zh) 作为a2a/a2b抑制剂的三唑并嘧啶
JP5636091B2 (ja) 癌治療に用いるためのコンブレタスタチン類似体
KR102800341B1 (ko) 헤테로사이클릭 유도체, 약학 조성물 및 암의 치료 또는 개선에서 그들의 용도
CN108602807B (zh) 杂环磺酰胺衍生物及含有其的药物
CN118574642A (zh) 作为治疗剂的肽微管蛋白抑制剂的肽缀合物
TW202024117A (zh) 抗紅血球生成素受體胜肽
CN117279629A (zh) 烯胺n-氧化物:合成及在缺氧响应性前药和显像剂中的应用
WO2016135138A1 (en) Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
AU2023285721B2 (en) Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
WO2025022003A1 (en) Beta-peptides with cytotoxic activity on cancer cells
HK40014041B (en) Myeloperoxidase imaging agents
HK40014041A (en) Myeloperoxidase imaging agents
BR112018015851B1 (pt) Composto, e, medicamento